Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.56 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | GFER | P55789 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | HTR1D | P28221 | 1/20 | 0.43 |
| ▸ | HTR1B | P28222 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5452393 | 0.93 | MAPT (0.51) | MAPTABCB1ABCC1SMN1; SMN2GFER | |
| SCHEMBL5456931 | 0.92 | MAPT (0.50) | MAPTABCB1ABCC1SMN1; SMN2GFER | |
| SCHEMBL5449891 | 0.92 | GFER (0.47) | MAPTABCB1ABCC1SMN1; SMN2GFER | |
| SCHEMBL5461787 | 0.92 | GFER (0.50) | MAPTABCB1ABCC1SMN1; SMN2GFER | |
| SCHEMBL5465922 | 0.91 | L3MBTL1 (0.48) | MAPTABCB1ABCC1L3MBTL1NPC1 | |
| SCHEMBL5455136 | 0.91 | NPC1 (0.49) | MAPTABCB1ABCC1SMN1; SMN2GFER | |
| SCHEMBL5456290 | 0.91 | MAPT (0.46) | MAPTABCB1ABCC1SMN1; SMN2GFER | |
| SCHEMBL5452259 | 0.91 | MAPT (0.46) | MAPTABCB1ABCC1SMN1; SMN2GFER | |
| SCHEMBL5445015 | 0.91 | NPC1 (0.58) | MAPTABCB1ABCC1NPC1KMT2A | |
| Ammonia Solution, Strong SCHEMBL5452545 | 0.90 | MAPT (0.46) | MAPTABCB1ABCC1SMN1; SMN2GFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070010526-A1 | Therapeutic isoquinoline compounds | ASTRAZENECA AB (SE) | 2007-01-11 | — | — | US | disclosed |
| US-20070010526-A1 | Therapeutic isoquinoline compounds | ASTRAZENECA AB (SE) | 2007-01-11 | — | — | US | disclosed |
| US-20070010526-A1 | Therapeutic isoquinoline compounds | ASTRAZENECA AB (SE) | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010526-A1 | Therapeutic isoquinoline compounds | HTR1B, HTR1D, HTR1A | MAPT 577/4885ABCB1 2319/4885ABCC1 3005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.